At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 220 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Upadacitinib (ABT-494) for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
In Brief
A Phase 2 clinical trial evaluating Placebo and ABT-494 for Crohn's Disease. Completed, enrolled 220 participants.
Detailed Summary
To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to Immunomodulators or anti-Tumor Necrosis Factor (TNF) therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartMar 2015
Primary CompletionNov 2016
Study CompletionAug 2017
TodayJul 2026
First PostedFeb 19, 2015
Enrollment StartMar 17, 2015
Primary CompletionNov 25, 2016
Study CompletionAug 3, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.4 years ago
Interventions
Placebodrug
Oral Dosing
ABT-494drug
Oral Dosing